Please login to the form below

Not currently logged in
Email:
Password:

Label change for Lilly's Livalo

The US Food and Drug Administration has said Eli Lilly & Company can update the label of cholesterol drug Livalo to remove a warning against the use of the drug together with HIV treatment lopinavir/ritonavir

The US Food and Drug Administration (FDA) has said Eli Lilly & Company can update the label of cholesterol drug Livalo (pitavastatin) to remove a warning against the use of the drug together with HIV treatment lopinavir/ritonavir.

The decision follows a study investigating the effects on patients when co-administered both treatments.

Data from the study demonstrated that there was no significant impact on the blood levels of participants, with minimal interaction between the two drugs.

"Livalo showed minimal drug-drug interactions with a common antiretroviral therapy HIV patients need to fight the disease," said Dr Judith Aberg, director of Virology, Bellevue Hospital Center and director, Division of Infectious Diseases and Immunology, NYU School of Medicine. "For a patient population that is taking multiple medications, this is exciting news."

Drugs to lower cholesterol, such as Livalo, are often prescribed to patients with HIV, with elevated cholesterol a complication associated with both the virus itself and antiretroviral therapies.

18th July 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Lucid Group Communications Limited

We are industry-leading thinkers when it comes to education. We use the latest academic thinking on the psychology of behaviour...

Latest intelligence

How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...
Medopad: the up and coming unicorn transforming remote patient monitoring
Blue Latitude Health speaks to Medopad’s Martha Carruthers to learn how the start-up’s modular apps are helping patients with complex diseases....

Infographics